Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 1 examiners • 0 of 2 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Yuhan Corporation has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. Both of these actions are assigned to 1 distinct examiner, MIKNIS, ZACHARY J, who is the busiest examiner with 2 pending office actions. The entire active portfolio is located within 1 distinct art unit. This represents a concentrated prosecution for the 2 pending matters currently under review.
The assignment of 2 pending office actions to MIKNIS, ZACHARY J means that a single individual is responsible for the company's entire active workload in the Biotechnology & Pharmaceuticals sector. Since there is only 1 distinct art unit involved, the 2 pending office actions likely relate to similar technical subject matter. This concentration in 1 distinct examiner and 1 distinct art unit simplifies the prosecution strategy but also increases the impact of that examiner's decisions on the 2 pending office actions.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MIKNIS, ZACHARY J | 2 | 68.5% | +32.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18562322 | COMPOSITION FOR COMBINATION THERAPY COMPRISING GROWTH DIFFERENTIATION FACTOR-15 VARIANT AND GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST | MIKNIS, ZACHARY J | — |
| 18513613 | COMPOSITION FOR PREVENTING OR TREATING NON-ALCOHOLIC FATTY LIVER DISEASE OR NON-ALCOHOLIC STEATOHEPATITIS COMPRISING GROWTH DIFFERENTIATION FACTOR-15 VARIANT | MIKNIS, ZACHARY J | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18562322 | COMPOSITION FOR COMBINATION THERAPY COMPRISING GROWTH DIFFERENTIATION FACTOR-15 VARIANT AND GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST | MIKNIS, ZACHARY J | — |
| 18513613 | COMPOSITION FOR PREVENTING OR TREATING NON-ALCOHOLIC FATTY LIVER DISEASE OR NON-ALCOHOLIC STEATOHEPATITIS COMPRISING GROWTH DIFFERENTIATION FACTOR-15 VARIANT | MIKNIS, ZACHARY J | — |
| Art Unit | Apps |
|---|---|
| 1658 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18562322 | COMPOSITION FOR COMBINATION THERAPY COMPRISING GROWTH DIFFERENTIATION FACTOR-15 VARIANT AND GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST | MIKNIS, ZACHARY J | 1658 | §101§102§112 | Non-Final OA | — | Pending | Nov 19, 2023 |
| 18513613 | COMPOSITION FOR PREVENTING OR TREATING NON-ALCOHOLIC FATTY LIVER DISEASE OR NON-ALCOHOLIC STEATOHEPATITIS COMPRISING GROWTH DIFFERENTIATION FACTOR-15 VARIANT | MIKNIS, ZACHARY J | 1658 | §101§102§112DP | Non-Final OA | — | Pending | Nov 19, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialYuhan Corporation has 2 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Zachary J Miknis has the most, with 2 of Yuhan Corporation's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
